Brief: Dishman Carbogen Amcis Says Unit Receives Drug Manufacturing License From NMPA For Shanghai Site
09/04/2025 16:12
April 9 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS: UNIT RECEIVES DRUG MANUFACTURING LICENSE FROM NMPA FOR SHANGHAI SITE Source text: ID:nBSE2rt290 Further company coverage: DSHM.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Dishman Carbogen Amcis
See all newsBrief: Dishman Carbogen Amcis Approves Raising Of Funds Via NCDs Worth Up To 380 Million Rupees
India's Dishman Carbogen Amcis falls after posting quarterly loss
Brief: Dishman Carbogen Amcis June-Quarter Consol Net Loss 578.8 Million Rupees
Brief: Dishman Carbogen Amcis Says Unit Successfully Completed GMP Inspection By China's NMPA For Shanghai Site
Brief: Dishman Carbogen Amcis Ltd Approves Issue Of Up To 1 Billion Rupees NCDs On Private Placement Basis